C
Cardiff Oncology Inc (CRDF)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.85
-0.00 (-0.15%)
Market Cap: $65.95M
Last updated: Nov 17, 2026 at 4:39 PM ET
Cardiff Oncology Inc (CRDF) Valuation Multiples
Cardiff Oncology (CRDF) trades at 115.3x sales and 2.3x book value. Its P/S of 115.3x is below its 5-year median of 200.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 115.3x |
| Price to book | 2.3x |
| PEG | N/A |
| FCF yield | -61.9% |
Historical Medians
Against its 10-year medians, its P/S is 30.7% below 166.4x and its P/B is 15.0% above 2.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 115.3x | 200.5x | 166.4x |
| P/B | 2.3x | 2.0x | 2.0x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 11.8x in 2018 to 866.8x in 2020.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $2.81 | 316.2x | 4.1x |
| 2024 | $4.34 | 291.4x | 2.5x |
| 2023 | $1.48 | 135.5x | 0.9x |
| 2022 | $1.40 | 158.7x | 0.6x |
| 2021 | $6.01 | 657.4x | 1.7x |
| 2020 | $17.99 | 866.8x | 3.3x |
| 2019 | $1.24 | 29.6x | 1.4x |
| 2018 | $3.15 | 11.8x | 1.2x |
| 2017 | $22.14 | 21.4x | 1.9x |
| 2016 | $151.23 | 166.0x | 3.3x |
Frequently Asked Questions About CRDF
What is CRDF's price to sales ratio?
Cardiff Oncology has a price to sales ratio of 115.3x.
CRDF pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors